Jazz Pharmaceuticals Plc (JAZZ)
241.55
+1.18
(+0.49%)
USD |
NASDAQ |
Nov 13, 16:00
241.57
+0.02
(+0.01%)
Pre-Market: 19:59
Jazz Pharmaceuticals Enterprise Value : 18.27B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 18.27B |
| November 12, 2026 | 18.20B |
| November 11, 2026 | 18.70B |
| November 10, 2026 | 18.52B |
| November 09, 2026 | 18.40B |
| November 06, 2026 | 17.84B |
| November 05, 2026 | 17.36B |
| November 04, 2026 | 17.83B |
| November 03, 2026 | 17.51B |
| November 02, 2026 | 16.53B |
| October 30, 2026 | 16.63B |
| October 29, 2026 | 16.11B |
| October 28, 2026 | 15.93B |
| October 27, 2026 | 16.04B |
| October 26, 2026 | 15.97B |
| October 23, 2026 | 16.51B |
| October 22, 2026 | 16.55B |
| October 21, 2026 | 16.38B |
| October 20, 2026 | 16.49B |
| October 19, 2026 | 16.15B |
| October 16, 2026 | 16.26B |
| October 15, 2026 | 16.53B |
| October 14, 2026 | 16.23B |
| October 13, 2026 | 16.27B |
| October 12, 2026 | 16.68B |
| Date | Value |
|---|---|
| October 09, 2026 | 16.79B |
| October 08, 2026 | 17.05B |
| October 07, 2026 | 17.61B |
| October 06, 2026 | 17.62B |
| October 05, 2026 | 17.92B |
| October 02, 2026 | 17.90B |
| October 01, 2026 | 17.72B |
| September 30, 2026 | 17.63B |
| September 29, 2026 | 17.27B |
| September 28, 2026 | 17.65B |
| September 25, 2026 | 17.63B |
| September 24, 2026 | 17.52B |
| September 23, 2026 | 17.43B |
| September 22, 2026 | 17.80B |
| September 21, 2026 | 17.86B |
| September 18, 2026 | 17.81B |
| September 17, 2026 | 18.01B |
| September 16, 2026 | 17.99B |
| September 15, 2026 | 17.82B |
| September 14, 2026 | 18.14B |
| September 11, 2026 | 18.14B |
| September 10, 2026 | 17.79B |
| September 09, 2026 | 17.85B |
| September 08, 2026 | 17.77B |
| September 04, 2026 | 18.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Avadel Pharmaceuticals Plc | -- |
| GH Research Plc | 948.78M |
| Cosmo NV | -- |
| Corcept Therapeutics, Inc. | 7.615B |
| Eli Lilly & Co. | 1.403T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -483.40M |
| Revenue (Quarterly) | 1.243B |
| Total Expenses (Quarterly) | 1.726B |
| EPS Diluted (Quarterly) | -7.471 |
| Gross Profit Margin (Quarterly) | 77.28% |
| Profit Margin (Quarterly) | -38.89% |
| Earnings Yield | 1.22% |
| Operating Earnings Yield | 7.34% |
| Normalized Earnings Yield | 5.124 |